Merck & Co.
|Founded||1891Merck (founded 1668) as a subsidiary of |
1917 as an independent company
|Headquarters||Kenilworth, New Jersey, United States|
|Kenneth C. Frazier|
Robert M. Davis
(President and CEO)
|Products||Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, Veterinary medicine (list...)|
|Revenue||US$47.994 billion (2020)|
|US$8.791 billion (2020)|
|US$7.067 billion (2020)|
|Total assets||US$89.800 billion (2020)|
|Total equity||US$29.270 billion (2020)|
Number of employees
|Footnotes / references|
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada,
Merck & Co. was established as an American affiliate in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has multiple blockbuster drugs or products each with 2020 revenues including cancer immunotherapy, anti-diabetic medication and vaccines against HPV and chickenpox.
The company develops medicines, vaccines, biologic therapies and animal health products. In 2020, the company had 6 blockbuster drugs or products, each with over $1 billion in revenue: Keytruda (pembrolizumab), a humanized antibody used in cancer immunotherapy that had $14.3 billion in 2020 revenue; Januvia (sitagliptin), an anti-diabetic medication used to treat type 2 diabetes that had $5.3 billion in 2020 revenue; Gardasil, an HPV vaccine that had $3.9 billion in 2020 revenue; Varivax, a varicella vaccine used to protect against chickenpox that had $1.9 billion in 2020 revenues; Bridion (Sugammadex), a neuromuscular-blocking drug that had $1.2 billion in 2020 revenue; and Pneumovax 23, a pneumococcal polysaccharide vaccine that had $1.1 billion in 2020 revenue. Other major products by the company include Isentress (raltegravir), an antiretroviral medication used to treat HIV/AIDS that had $857 million in 2020 revenue; Simponi (golimumab), a human monoclonal antibody used as an immunosuppressive drug that had $838 million in 2020 revenue; RotaTeq, a rotavirus vaccine that had $797 million in 2020 revenue; and Lynparza (olaparib), a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults that generated $725 million in 2020 revenue for the company.
Details of Merck's major products are as follows:
- Januvia (sitagliptin) is a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. In 2013, Januvia was the second largest selling diabetes drug worldwide. Januvia is commonly paired with the generic anti-diabetes drug metformin. It has been popular due in part because unlike many other diabetes drugs, it causes little or no weight gain and is not associated with hypoglycemic episodes. Merck also sells a single pill combination drug containing both Januvia and metformin under the trade name Janumet. There has been some concern that treatment with Januvia and other DPP-IV inhibitors may be associated with a modestly increased risk of pancreatitis.
- Zetia (ezetimibe) is a drug for hypercholesterolemia that acts by inhibiting the absorption of dietary cholesterol. Zetia has been controversial, as it was initially approved based on its impact on serum cholesterol levels without proof that it actually impacted the incidence of cardiovascular disease. Results of the IMPROVE-IT study, however, introduced at the 2014 Scientific Sessions of the American Heart Association, showed a statistically significant, albeit modest, benefit in adding Zetia to simvastatin for high-risk, post-acute-coronary-syndrome patients.
- Remicade (infliximab) is a monoclonal antibody directed toward the cytokine TNF-alpha and used for the treatment of a wide range of autoimmune disorders, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis, and others. Remicade and other TNF-alpha inhibitors exhibit additive therapeutic effects with methotrexate and improve quality of life. Adverse effects include increased risk of infection and certain cancers. Merck had rights to the drug in certain areas, while Janssen Biotech had rights in other areas; in 2017, Merck announced a biosimilar to Remicade, Renflexis.
- Gardasil (recombinant human papilloma virus vaccine) is a vaccine against multiple serotypes of human papilloma virus (HPV), which is responsible for most cases of cervical cancer worldwide.
- Isentress (raltegravir) is a human immunodeficiency virus integrase inhibitor for the treatment of HIV infection. It is the first anti-HIV compound having this mechanism of action. It is part of one of several first line treatment regimens recommended by the United States Department of Health and Human Services.
- Keytruda (pembrolizumab) is an immune modulator for the treatment of cancer. On September 4, 2014, the US Food and Drug Administration (FDA) approved Pembrolizumab (MK-3475) as a breakthrough therapy for melanoma treatment. In clinical trials, pembrolzumab provided partial tumor regression in about one quarter of patients, many of whom have not seen further progression of their disease in over 6 months of follow-up.
- Invanz (Ertapenem) is an injectable antibiotic, rights to which Merck has owned since 1999. Merck was in a legal dispute with the Taiwanese company Savior Lifetec over their attempt to secure rights to sell a generic drug version in the United States. Savior has since obtained approval to market generic ertapenem.
- Mexsana is an antiseptic medicated powder.
- Molnupiravir is an antiviral pill to treat covid-19, developed in partnership with Ridgeback Biotherapeutics.
Merck & Co. publishes The Merck Manuals, a series of medical reference books for physicians, nurses, technicians, and veterinarians. These include the Merck Manual of Diagnosis and Therapy, the world's best-selling medical reference. The Merck Index, a compendium of chemical compounds, was published by Merck & Co. until it was acquired by the Royal Society of Chemistry in 2012.
Roots and early history
Merck & Co. traces its origins to its former German parent company Merck Group, which was established by the Merck family in 1668 when Friedrich Jacob Merck purchased a drug store in Darmstadt. In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of morphine. Merck perfected the chemical process of deriving morphine from opium and later introduced cocaine, used to treat sinus problems and to add to beverages to boost energy levels.
In 1887 a German-born, long-time Merck employee, Theodore Weicker, went to the United States to represent Merck Group. In 1891, family member George (Georg) Merck emigrated to the United States and set up Merck & Co. in New York as the U.S. subsidiary of Merck Group. In 1891, with a capital of $200,000 received from E. Merck, Weicker started Merck & Co., with headquarters in lower Manhattan. That year George Merck, the 23-year-old son of the then head of E. Merck (and grandson of the founder) joined Weicker in New York. Merck & Co. operated from 1891 to 1917 as the US subsidiary of the Merck Group.
After the U.S. entered World War I, due to its German connections, Merck & Co. was the subject of expropriation under the Trading with the Enemy Act of 1917. In 1919, at a U.S. government auction, in partnership with Goldman Sachs and Lehman Brothers, George W. Merck bought back the company for $3.5 million, but Merck & Co. remained a separate company from its former German parent. Merck & Co. holds the trademark rights to the "Merck" name in the United States and Canada, while its former parent company retains the rights in the rest of the world; the right to use the Merck name was the subject of litigation between the two companies in 2016.
In 1929, H. K. Mulford Company merged with Sharp and Dohme, Inc. and brought vaccine technology, including immunization of cavalry horses in World War I and delivery of a diphtheria antitoxin to Merck & Co.
In 1943, Streptomycin was discovered during a Merck-funded research program in Selman Waksman's laboratory at Rutgers University. It became the first effective treatment for tuberculosis. At the time of its discovery, sanitoriums for the isolation of tuberculosis-infected people were a ubiquitous feature of cities in developed countries, with 50% dying within 5 years of admission. Although Merck's agreement with Rutgers gave it exclusive rights to streptomycin, at Wakman's request the company renegotiated the agreement, returning the rights to the university in exchange for a royalty. The university then set up non-exclusive licenses with seven companies to ensure a reliable supply of the antibiotic.
1950 to 2000
In the 1950s, thiazide diuretics were developed by Merck scientists Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello and led to the marketing of the first drug of this class, chlorothiazide, under the trade name Duiril in 1958. The research leading to the discovery of chlorothiazide, leading to "the saving of untold thousands of lives and the alleviation of the suffering of millions of victims of hypertension" was recognized by a special Public Health Award from the Lasker Foundation in 1975.
In 1953, Merck & Co. merged with Philadelphia-based Sharp & Dohme, Inc., becoming the largest U.S. drugmaker. Sharp and Dohme had acquired H. K. Mulford Company in 1929, adding smallpox vaccines to its portfolio. The combined company kept the trade name Merck in the United States and Canada, and as Merck Sharp & Dohme (MSD) outside North America.
In 1965, Merck & Co. acquired Charles Frosst Ltd. of Montreal (founded 1899), creating Merck-Frosst Canada, Inc., as its Canadian subsidiary and pharmaceutical research facility. Merck & Co. closed this facility in July 2010 but remerged in 2011 as Merck Canada.
Maurice Hilleman, a scientist at Merck, developed the first mumps vaccine in 1967, the first rubella vaccine in 1969, and the first trivalent measles, mumps, rubella (MMR vaccine) in 1971. The incidence of rubella-associated birth defects fell from up to 10,000 per year in the U.S. to zero in the aftermath of the rubella vaccine's development. Hilleman also developed the first Hepatitis B vaccine and the first varicella vaccine, for chickenpox.
The company was incorporated in New Jersey in 1970.
Merck scientist William C. Campbell and Satoshi Ōmura developed ivermectin for veterinary use in 1981, and later put it to human use against Onchocerciasis in 1987-88 with the name Mectizan; today the compound is used against river blindness, lymphatic filariasis, scabies and other parasitic infections.
In 1982, the company formed a joint venture, KBI Inc., with AstraZeneca. During the late 1980s and 1990s, the company also established joint ventures with DuPont to access research and development expertise, and with Johnson & Johnson to sell over-the-counter consumer medications.
In 1985, Merck received approval for imipenem, the first member of the carbapenem class of antibiotics. Antibiotics of the carbapenem class play an important role in treatment guidelines for certain hospital-acquired and multi-drug resistant infections.
In 1991, Merck's Kelco subsidiary was responsible for volatile organic compound (VOC) emission pollution in the San Diego area. In 1996 Merck paid $1.8 million for polluting the air. New machines were installed to reduce smog emissions by 680,000 lb (310,000 kg) a year.
2001 to 2019
From 2002 through 2005, the Australian affiliate of Merck paid publishing house Elsevier an undisclosed amount to produce eight issues of a medical journal, the Australasian Journal of Bone and Joint Medicine. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx. The CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable".
In November 2009, Merck & Co. completed a merger with Schering-Plough in a US$41 billion deal. Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co. was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc. The maneuver was an attempt avoid a "change-of-control" in order to preserve Schering-Plough's rights to market Remicade. A settlement with Johnson & Johnson was reached in 2011, in which Merck agreed to pay $500 million. Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent.
In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce.
Between 2010 and 2015, the company cut around 36,450 jobs. During that time, the company sold its consumer health business to Bayer and narrowed the company's focus to immunology, vaccines, diabetes, emerging markets and medicines used in hospitals, like certain antibiotics.
In July 2015, Merck and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for the Abylnx. The company also announced it would spend $95 million up front collaborating with cCAM Biotherapeutics and its early-stage treatment similar to Keytruda. Merck & Co. will bring in CM-24, an antibody designed to block the immune checkpoint CEACAM1.
In January 2016, Merck announced two new partnerships; the first with Quartet Medicine and its small molecule pain treatments, the second with Complix investigating intracellular cancer targets, with both collaborations potentially generating up to $595 million and $280 million respectively. Days later the company announced it would acquire IOmet Pharma, with IOmet becoming a wholly owned subsidiary of Merck & Co. The acquisition includes IOmets indoleamine-2,3-dioxygenase 1 (IDO), tryptophan 2,3-dioxygenase (TDO), and dual-acting inhibitors.
In July 2016, the company acquired Afferent Pharmaceuticals, developer of a candidate used to block P2RX3 receptors, for approximately $1 billion, plus up to $750 million in milestone payments.
In April 2017, Merck Animal Health acquired Vallée S.A., a Brazilian animal health product manufacturer.
In 2018, Merck began the submission process for a Biologics License Application to the Food and Drug Administration under the Breakthrough Therapy Designation for an investigational vaccine, called V920, to fight the Zaire strain of the Ebola virus.
In April 2019, the company acquired Immune Design for approximately $300 million, gaining access to its immunotherapy programs. It also acquired Antelliq Group for $2.4 billion, or $3.7 billion including debt.
In June 2019, Merck announced it would acquire Tilos Therapeutics for up to $773 million.
In November 2019, the company acquired Calporta, which focused on Parkinsons and Alzheimers treatments.
2020 to present
Also in June 2020, Merck Animal Health acquired Quantified Ag, a data and analytics company that monitors cattle body temperature and movement in order to detect illness early.
In August 2020, Merck Animal Health acquired IdentiGEN, engaged in DNA-based animal traceability.
In November 2020, Merck announced it would acquire VelosBio for $2.75 billion, developer of VLS-101, an antibody-drug conjugate designed to target Tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors. VLS-101 is currently Phase I and Phase II clinical trials. The company also announced it would acquire OncoImmune for $425 million and its phase 3 candidate, CD24Fc, used in the treatment of patients with severe and critical COVID-19.
In February 2021, Merck Animal Health acquired PrognostiX Poultry.
In June 2021, the U.S. government agreed to spend $1.2 billion to purchase 1.7 million doses of Molnupiravir, a Merck product, if it were to be approved by regulators to treat COVID-19. In October 2021, the company said that the drug reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of COVID-19 and that it would seek Emergency Use Authorization for the drug.
Merck Company Foundation
Since it was founded in 1957, the Merck Company Foundation has distributed $740 million in overall charitable distributions including more than $480 million to educational and non-profit organizations.
Patient assistance programs
Merck & Co. was one of the first American pharmaceutical companies to offer assistance to those unable to afford its medications, beginning a program in the 1950s. Merck & Co. offers seven patient assistance programs, each with specific eligibility requirements.
Merck and the Wellcome trust jointly fund the Hilleman Laboratories, an India-based non-profit research organization dedicated to the development of low-cost vaccines for use in developing countries. Current projects include the development of low cost, thermostable vaccines for the prevention of cholera, rotavirus, and meningitis.
Merck for Mothers
Merck for Mothers is Merck’s global initiative to help create a world where no woman has to die while giving life. 
Mectizan donation program
In 1987, Merck began a program with UNICEF to donate its new drug Mectizan to "all that need it for as long as needed" in an effort to combat onchocerciasis, also known as river blindness, primarily in Africa. Up to that point, the World Health Organization had fought the disease through the use of insecticides to lower the population of its primary vector, the Black Fly. However, when studies in the 1980s showed how effective the drug was at treating and preventing the disease, the WHO agreed to use it instead of its previous strategies. Merck's involvement is considered a key factor in the success against the disease all over the world, and the decision to donate the entirety of the drug to all those in need of it is used as part of the Mectizan Donation Program that covers countries such as Yemen and African countries. More than 700 million people have been treated since the inception of the program with 80 million people still undergoing treatment in Africa, Latin America, and Yemen. Blindness caused by onchocerciasis is decreasing, and there are regions of Latin America and Africa that have been shown to have completely eliminated the disease altogether.
In 1999, the U.S. Food and Drug Administration (FDA) approved Vioxx (known generically as rofecoxib), a Merck product for treating arthritis. Vioxx was designed as a selective inhibitor of the enzyme cyclooxygenase-2. Such compounds were expected to cause less gastrointestinal bleeding than older anti-inflammatory drugs such as naproxen, which were associated with 20,000 hospitalizations and 2000 deaths each year.[non-primary source needed] Vioxx became one of the most prescribed drugs in history.
Thereafter, studies by Merck and by others found an increased risk of heart attack associated with Vioxx use when compared with naproxen. Merck adjusted the labeling of Vioxx to reflect possible cardiovascular risks in 2002.
On September 23, 2004, Merck received information about results from a clinical trial it was conducting that included findings of increased risk of heart attacks among Vioxx users who had been using the medication for over eighteen months. On September 28, 2004, Merck notified the FDA that it was voluntarily withdrawing Vioxx from the market, and it publicly announced the withdrawal on September 30. An analysis for the period 1999–2004, based on U.S. Medical Expenditure Survey data, reported that Vioxx was associated with 46,783 heart attacks, and along with the other popular COX-2 inhibitor Celebrex, an estimated 26,603 deaths from both.[non-primary source needed]
About 50,000 people sued Merck, claiming they or their family members had suffered medical problems such as heart attacks or strokes after taking Vioxx. In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement required that claimants provide medical and pharmacy records confirming the occurrence of a heart attack, ischemic stroke, or sudden cardiac death; the receipt of at least 30 Vioxx pills within 60 days prior to the injury or death; and confirmation of Vioxx being used within 14 days of the Vioxx-related event. The settlement was generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached between $10 billion and $25 billion. As of mid-2008, when the plaintiff class had reached the threshold percentage required by Merck to go through with the settlement, plaintiffs had prevailed in only three of the twenty cases that had reached juries, all with relatively small awards.
Merck has refused to consider compensation for Vioxx victims and their families outside the US. This is particularly true in the UK where there are at least 400 victims and the legal protection afforded to the victims and their families is particularly weak.
According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralized" or "discredited". "We may need to seek them out and destroy them where they live," wrote an employee. A Stanford Medical School professor said that Merck was engaged in intimidation of researchers and infringement upon academic freedom.
On May 20, 2008, Merck settled for $58 million with 30 states alleging that Merck engaged in deceptive marketing tactics to promote Vioxx. All its new television pain-advertisements must be vetted by the Food and Drug Administration and changed or delayed upon request until 2018.
Fosamax (alendronate) is a bisphosphonate used for the treatment of post-menopausal osteoporosis and for the prevention of skeletal problems in certain cancers. The American College of Clinical Endocrinology, the American College of Obstetricians and Gynecologists, the North American Menopause Society and the UK National Osteoporosis Guideline Group recommend alendronate and certain other bisphosphonates as first line treatments for post-menopausal osteopotosis. Long-term treatment with bisphosponates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. Alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%.
In December 2013, Merck agreed to pay a total of $27.7 million to 1,200 plaintiffs in a class action lawsuit alleging that the company's osteoporosis drug had caused them to develop osteonecrosis of the jaw. Prior to the settlement, Merck had prevailed in 3 of 5 so-called bellwether trials. Approximately 4000 cases still await adjudiction or settlement as of August 2014.
A fraud investigation by the United States Department of Justice began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act. They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers. On February 7, 2008, Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The settlement was one of the largest pharmaceutical settlements in history. The federal government received more than $360 million, plus 49 states and Washington, DC, received over $290 million. One whistleblower received a $68 million reward. Merck made the settlement without an admission of liability or wrongdoing.
"Merck" name legal dispute
In 191 of 193 countries, the original Merck company, the Merck Group of Darmstadt, owns the rights to the "Merck" name. In the United States and Canada, the company trades under the name EMD (an abbreviation of Emanuel Merck, Darmstadt), its legal name here says Merck KGaA, Darmstadt, Germany, and instead of "Merck Group", the "EMD Group" name is used. In the United States and Canada, Merck & Co. holds the rights to the trademark "Merck", while in the rest of the world the company trades under the name MSD (an abbreviation of Merck, Sharp & Dohme) and its legal name says here Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA.
In 2015 the Merck Group adopted a new logo and said it will be "much more aggressive" about protecting the brand of "the real Merck". Merck of Darmstadt has initiated litigation against its former subsidiary, Merck & Co. (MSD) of Kenilworth, in several countries over infringing use of the Merck name. In 2016, the High Court of Justice in the United Kingdom ruled that MSD had breached an agreement with its former parent company and that only Merck of Darmstadt is entitled to use the Merck name in the United Kingdom. The judge also held that MSD's use of "Merck" as part of branding on its global websites were directed to the UK and infringed Merck's trade mark rights in the UK.
In response to the ruling, MSD initiated counter-litigation in the United States in January 2016 by filing a federal lawsuit which accused its former parent company of "infringing on its trademark" through actions that included the increased usage of “Merck KGaA” and “MERCK” in branding in the US as well as on its social media presence. Further Merck & Co. has also accused the Merck Group of federal trademark dilution, unfair competition, false advertising, deceptive trade practices, breach of contract, and cybersquatting. The case came to a head when a research scientist believed he was communicating with Merck & Co regarding a research grant in oncology, when in fact he was talking with the Merck Group. As a result, Merck & Co. asked the federal court to stop the Merck Group from using “Merck” on any products or marketing materials in the United States. As a direct result, Merck & Co is seeking “all monetary gains, profits, and advantages” made by the Merck Group and three-times the damage, plus additional punitive damages.
In April 2020, in the course of litigation of Merck against MSD in Switzerland, the Federal Supreme Court of Switzerland ruled that MSD's use of the "Merck" brand in its global websites could, absent geotargeting mechanisms, have "commercial effect" in Switzerland and could therefore violate Merck's rights (if any) to the "Merck" brand in Switzerland.
Merck & Co. once used methylene chloride, an animal carcinogen on the United States Environmental Protection Agency's list of pollutants, as a solvent in some of its manufacturing processes. Merck chemists and engineers subsequently replaced the compound with others having fewer negative environmental effects. Merck has also modified its equipment to protect the environment, installing a distributed control system that coordinates chemical reactions more efficiently and expedites manufacturing by 50 percent, eliminating the need for the disposal and storage of harmful waste. Biological oxygen demand has also been reduced. In 2011, Merck paid a $1.5 million civil penalty to settle alleged violations of federal environmental laws at its pharmaceutical manufacturing facilities in Riverside, Pennsylvania and West Point, Pennsylvania.
- "Merck & Co., Inc. 2020 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- Trentmann, Nina (March 24, 2021). "Merck Names 30-Year Company Veteran as CFO". The Wall Street Journal. ISSN 0099-9660.
- "Merck Appoints Caroline Litchfield Chief Financial Officer". Business Wire. March 24, 2021.
- Linnane, Ciara (March 24, 2021). "Merck names Treasurer Caroline Litchfield CFO effective April 1". MarketWatch.
- "Fortune 500: Merck & Co". Fortune.
- "Forbes Global 2000: Merck & Co". Forbes.
- Palmer, Eric (June 17, 2014). "The top 10 best-selling diabetes drugs of 2013". FiercePharma.
- Zhan M, Xu T, Wu F, Tang Y (August 2012). "Sitagliptin in the treatment of type 2 diabetes: a meta-analysis". Journal of Evidence-Based Medicine. 5 (3): 154–65. doi:10.1111/j.1756-5391.2012.01189.x. PMID 23672222. S2CID 205981406.
- Deacon CF, Mannucci E, Ahrén B (August 2012). "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis". Diabetes Obes Metab. 14 (8): 762–7. doi:10.1111/j.1463-1326.2012.01603.x. PMID 22471248. S2CID 21833823.
- Li L, Shen J, Bala MM, et al. (2014). "Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies". The BMJ. 348: g2366. doi:10.1136/bmj.g2366. PMC 3987051. PMID 24736555.
- "AHA: IMPROVE-IT Proves Ezetimibe Benefit". MedpageToday. November 17, 2014.
- Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M (2012). "Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis". PLOS One. 7 (1): e30275. Bibcode:2012PLoSO...730275A. doi:10.1371/journal.pone.0030275. PMC 3260264. PMID 22272322.
- "Merck and Johnson & Johnson Reach Agreement on Distribution Rights for Remicade and Simponi" (Press release). Business Wire. April 15, 2011. Archived from the original on 2012-07-08.
- "Merck, Samsung Bioepis Launch Remicade Biosimilar in U.S." genengnews.com. July 24, 2017.
- "HIGHLIGHTS OF PRESCRIBING INFORMATION: GARDASIL" (PDF). Merck.
- "HIGHLIGHTS OF PRESCRIBING INFORMATION: ISENTRESS" (PDF). Merck.
- "Drug Database: Raltegravir". HIV.gov.
- "Merck Melanoma Drug Is First PD-1 Inhibitor OK'd by FDA". genengnews.com. September 5, 2014.
- "HIGHLIGHTS OF PRESCRIBING INFORMATION: Keytruda" (PDF). Food and Drug Administration.
- Jeffrey, Jeff (August 25, 2015). "Merck sues Taiwan company over generic antibiotic product". American City Business Journals.
- "LABEL: ERTAPENEM- ertapenem sodium injection". National Institutes of Health.
- Zimmer, Carl (2021-06-17). "A Pill to Treat Covid-19? The U.S. Is Betting on It". The New York Times. ISSN 0362-4331. Retrieved 2021-06-24.
- "Key Facts About Merck". The New York Times. Associated Press. November 3, 2005.
- Voinea, Cosmina Lelia; Kranenburg, Hans Van (July 14, 2017). Nonmarket Strategic Management. Taylor & Francis. ISBN 978-1-317-42173-3.
- "The history of heroin: From King Tut to cough remedy". The Palm Beach Post. June 28, 2018.
- "Opioid epidemic shares chilling similarities with past drug crises". Stat. Associated Press. October 29, 2017.
- Wilkins, Mira (1989). The History of Foreign Investment in the United States to 1914. ISBN 9780674396661.
- "This month in 1917: A tale of two Mercks". PM Live. April 14, 2014.
- "With Merck & Co. Offering, Goldman Sachs Emerges from the Shadow of World War I". Goldman Sachs.
- "Legal Wrangle Pits Merck vs. Merck". genengnews.com. January 15, 2016.
- Bulik, Beth Snyder (June 1, 2020). "In another round of Merck vs. Merck, Germany-based Merck KGaA notches a win in the U.K." FiercePharma.
- Dauer, Ulrike. "Germany's Merck KGaA Wins Battle Over Name in U.K.". The Wall Street Journal.
- "Fight over Merck name sees German firm win in British court". Reuters. January 15, 2016.
- Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". J Hist Med Allied Sci. 59 (3): 441–62. doi:10.1093/jhmas/jrh091. PMID 15270337. S2CID 27465970.
- Antibacterial Agents. Chemistry, Mode of Action, Mechanisms of Resistance, and Clinical Applications. Anderson RJ, Groundwater PJ, Todd A, Worsely AJ. Wiley (2012). ISBN 9780470972458 See Preface material.
- Tansey, E.M.; Reynolds, L.A., eds. (2000). Post-Penicillin Antibiotics: From Acceptance to Resistance?. A Witness Seminar held at the Wellcome Institute for the History of Medicine, London. London: Wellcome Trust. ISBN 978-184129-012-6.
- Beyer KH (1993). "Chlorothiazide. How the thiazides evolved as antihypertensive therapy". Hypertension. 22 (3): 388–91. doi:10.1161/01.hyp.22.3.388. PMID 8349332.
- "Drugs@FDA: FDA Approved Drug Products".
- "The Lasker Foundation—Awards".
- Galambos, Louis; Sewell, Jane Eliot (August 13, 1997). Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995. Cambridge University Press. ISBN 978-0-521-62620-0.
- Esparza, José; Lederman, Seth; Nitsche, Andreas; Damaso, Clarissa R. (June 2020). "Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry". Vaccine. 38 (30): 4773–4779. doi:10.1016/j.vaccine.2020.05.037. PMC 7294234. PMID 32473878.
- Schrick, Livia; Tausch, Simon H.; Dabrowski, P. Wojciech; Damaso, Clarissa R.; Esparza, José; Nitsche, Andreas (12 October 2017). "An Early American Smallpox Vaccine Based on Horsepox". New England Journal of Medicine. 377 (15): 1491–1492. doi:10.1056/NEJMc1707600. PMID 29020595.
- Esparza, José; Lederman, Seth; Nitsche, Andreas; Damaso, Clarissa R. (19 June 2020). "Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry". Vaccine. 38 (30): 4773–4779. doi:10.1016/j.vaccine.2020.05.037. PMC 7294234. PMID 32473878.
- "CORPORATIONS: Merck's Merger". Time. March 16, 1953.
- "Then and Now". Chemical Institute of Canada. November 2014.
- "Montreal plant among 17 closed by drugmaker Merck". Toronto Star. July 8, 2010.
- "Mumps—History of Vaccines". College of Physicians of Philadelphia.
- "Rubella". College of Physicians of Philadelphia.
- "1971-MMR Combination Vaccine Debuts". College of Physicians of Philadelphia.
- "Abnormal Development - Rubella Virus".
- "Chickenpox: Attenuated Strain Licensed in U.S."
- "Merck History".
- Crump, Andy; Omura, Satoshi (2011). "Ivermectin, 'Wonder drug' from Japan: The human use perspective". Proceedings of the Japan Academy, Series B. 87 (2): 13–28. Bibcode:2011PJAB...87...13C. doi:10.2183/pjab.87.13. PMC 3043740. PMID 21321478.
- "Satoshi Omura PhD". Retrieved 5 October 2015.
- Press release NobelPrize.org
- "Japanese microbiologist Satoshi Omura shares Nobel Prize for medicine". The Japan Times. 5 October 2015. Retrieved 5 October 2015.
- "Joint Ventures and Other Equity Method Affiliates". U.S. Securities and Exchange Commission. December 31, 2014.
- Solomkin, J. S.; Mazuski, J. E.; Bradley, J. S.; Rodvold, K. A.; Goldstein, E. J.; Baron, E. J.; O'Neill, P. J.; Chow, A. W.; Dellinger, E. P.; Eachempati, S. R.; Gorbach, S.; Hilfiker, M.; May, A. K.; Nathens, A. B.; Sawyer, R. G.; Bartlett, J. G. (2010). "Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clinical Infectious Diseases. 50 (2): 133–164. doi:10.1086/649554. PMID 20034345.
- "U.S. SETTLES $1.8 MILLION POLLUTION CASE WITH MERCK AND MONSANTO". United States Environmental Protection Agency. September 5, 1996.
- "Merck & Co. completes Medco purchase". The Baltimore Sun. November 19, 1993. Archived from the original on May 29, 2019.
- JOHNSON, LINDA A. (November 18, 1993). "Merck Completes $6 Billion Merger With Medco". Associated Press.
- "Merck finally spins off Medco Health to shareholders". USA Today. Associated Press. August 20, 2003.
- Singer, Natasha (May 13, 2009). "Merck paid for medical 'journal' without disclosure". The New York Times.
- Lowe, Derek (May 11, 2009). "Merck, Elsevier, and Fakery". Science.
- "Statement from Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005" (Press release). Elsevier. May 7, 2009.
- SILBERNER, JOANNE (May 6, 2005). "Merck CEO Gilmartin Steps Down". NPR.
- Singer, Natasha (March 10, 2009). "Merck to Buy Schering-Plough for $41.1 Billion". The New York Times.
- Berkrot, Bill; Pierson, Ransdell (November 3, 2009). "Merck, Schering-Plough set to complete merger". Reuters.
- Edwards, Jim (November 10, 2009). "Merck Legally Changed Its Name 3 Times to Achieve Reverse Merger With Schering". CBS News.
- "Merck, Johnson & Johnson reach Remicade, Simponi deal". American City Business Journals. April 15, 2011.
- Rubin, Ben Fox (October 6, 2011). "Merck Chairman Clark To Retire; CEO Frazier to Take Over". The Wall Street Journal.
- Smith, Aaron (October 1, 2013). "Merck to cut 8,500 more jobs". CNN.
- "Merck cuts another 8,500 jobs". BBC News. October 1, 2013.
- Kinch MS, Haynesworth A, Kinch SL, Hoyer D (August 2014). "An overview of FDA-approved new molecular entities: 1827-2013". Drug Discovery Today. 19 (8): 1033–9. doi:10.1016/j.drudis.2014.03.018. PMID 24680947.
- "Merck Completes Tender Offer to Acquire Idenix" (Press release). Business Wire. August 5, 2014.
- "Merck acquires Idenix". genengnews.com. June 9, 2014.
- "Merck Buys OncoEthix for up to $375M". genengnews.com. December 18, 2014.
- "Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers" (Press release). Business Wire. December 18, 2014.
- Staton, Tracy (August 13, 2015). "Merck tallies 36,000 job cuts in 5 years of restructuring". FiercePharma.
- "Merck Completes Tender Offer to Acquire Cubist" (Press release). Business Wire. January 21, 2015.
- "Ablynx, Merck & Co. Ink $4B+ Expansion of Immuno-Oncology Collaboration". genengnews.com.
- "Merck signs a $605M deal to bulk up in cancer immunotherapy". FierceBiotech. July 28, 2015.
- "Quartet, Merck Partner on Pain Treatments in Up-to-$595M Alliance". genengnews.com. January 6, 2016.
- "Merck & Co. Launches Up-to-$280M Cancer Collaboration with Complix". genengnews.com. January 6, 2016.
- "Merck & Co. Acquires Cancer Immunotherapy Developer IOmet". genengnews.com. January 11, 2016.
- "Acquisitions, Divestitures, Research Collaborations and License Agreements". U.S. Securities and Exchange Commission.
- "Merck & Co. to Acquire Afferent Pharmaceuticals for Up to $1.25B". genengnews.com. June 10, 2016.
- "Merck Animal Health Completes Acquisition of Vallée S.A." (Press release). Business Wire. March 22, 2017.
- "Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise". genengnews.com. September 6, 2017.
- "Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology" (Press release). Business Wire. September 6, 2017.
- Bie, Ephraim (June 20, 2018). "Merck & Co. completes Viralytics acquisition". S&P Global.
- "FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus" (Press release). Business Wire. September 17, 2019.
- Babu, Aakash Jagadeesh (February 21, 2019). "Merck to buy immunotherapy developer Immune Design for $300 million". Reuters.
- "Merck Completes Tender Offer to Acquire Immune Design" (Press release). Business Wire. April 2, 2019.
- "Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals" (Press release). Business Wire. April 1, 2019.
- Repko, Melissa (September 20, 2019). "Peloton Therapeutics' $2.2 billion deal with Merck took root with an idea for clinical trials". The Dallas Morning News.
- Mathias, Tamara (June 10, 2019). "Merck to buy Tilos Therapeutics for up to $773 million". Reuters.
- "COI Pharmaceuticals Announces Acquisition of Calporta by Merck" (Press release). Business Wire. November 13, 2019.
- "Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare" (Press release). Business Wire. December 17, 2019.
- "Merck Completes Acquisition of ArQule" (Press release). Business Wire. January 16, 2020.
- "Inaugural Manufacturing Awards". New Jersey Business magazine. March 11, 2020.
- "Merck Completes Acquisition of Themis" (Press release). Business Wire. June 19, 2020.
- "Merck to Acquire Themis".
- Erman, Julie Steenhuysen (May 26, 2020). "Merck to buy Austrian vaccine maker as it jumps into COVID-19 race". Reuters.
- "Merck Animal Health Completes Acquisition of Quantified Ag®" (Press release). Business Wire. June 17, 2020.
- "Merck Animal Health Completes Acquisition of IdentiGEN" (Press release). Business Wire. August 5, 2020.
- "Merck to buy $1 billion stake in Seattle Genetics, co-develop cancer therapy". Reuters. 14 September 2020.
- Roy, Trisha (September 14, 2020). "Merck to buy $1 bln stake in Seattle Genetics, co-develop cancer therapy". Reuters.
- "Merck Snaps up VelosBio and its ROR1 Inhibitor in $2.75 Billion Deal".
- O'Donnell, Carl (November 23, 2020). "Merck adds experimental COVID-19 therapy with OncoImmune deal". Reuters.
- "Merck Bolsters COVID-19 Pipeline with OncoImmune Acquisition".
- "Merck Animal Health Completes Acquisition of Poultry Sense Limited" (Press release). Business Wire. February 25, 2021.
- "Merck Completes Acquisition of Pandion Therapeutics" (Press release). Business Wire. April 1, 2021.
- "Merck to buy drug developer Pandion Therapeutics for $1.85 billion". Reuters. 25 February 2021.
- "Merck Snaps up Autoimmune-Focused Pandion in Massive $1.85 Billion Deal".
- Schumaker, Erin (June 9, 2021). "Merck signs $1.2 billion deal with US government for experimental COVID treatment". ABC News.
- Taylor, Chloe (October 1, 2021). "Merck says its new Covid pill reduces the risk of hospitalization, death by half for some patients". CNBC.
- Schmidt, Ann (July 1, 2021). "Merck's new CEO Robert Davis begins, after Ken Frazier's retirement". FOXBusiness.
- Bomey, Nathan (February 4, 2021). "Kenneth Frazier stepping down as Merck CEO, becomes executive chairman". USA TODAY.
- Williams, Jordan (February 4, 2021). "Merck CEO stepping down at end of June". TheHill.
- Brown, Courtenay (February 4, 2021). "Merck's Ken Frazier, one of just 4 Black CEOs in the Fortune 500, is stepping down". Axios.
- "Merck Announces Completion of Organon & Co. Spinoff" (Press release). Business Wire. June 3, 2021.
- "Merck to Acquire Acceleron Pharma Inc" (Press release). Business Wire. September 30, 2021.
- "SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) IDENIX PHARMACEUTICALS, INC. IMPERIAL BLUE CORPORATION" (PDF). U.S. Securities and Exchange Commission.
- "Merck & Co., Inc. - Financials - SEC Filings - SEC Filings Details".
- "SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Immune Design Corp" (PDF). U.S. Securities and Exchange Commission.
- "Foundation » Merck Responsibility". Merck Responsibility.
- "Princeton University and The Merck Company Foundation Announce Creation Of New Global Health Scholars Program and Lecture Series" (PDF). May 22, 2007.
- Rushe, Dominic (December 10, 2012). "Boy Scouts of America: Merck pulls funding in protest at gay ban". The Guardian.
- "Merck to Create New Patient Assistance Program for Vaccines" Retrieved May 20, 2008. Archived September 16, 2008, at the Wayback Machine
- "Patient Assistance – Available Prescription Assistance Programs From Merck & Co." Retrieved May 20, 2008.
- Merck Patient Assistance Programs Archived July 27, 2011, at the Wayback Machine
- Helfand, Carly (June 20, 2014). "Merck JV plans to show up J&J, Sanofi with low-cost cholera vaccine". FiercePharma. Archived from the original on 2015-02-07.
- "MerckforMothers.com". 4 March 2021.
- "Merck & Co & UNICEF USA's Partnership to Save and Protect Children". UNICEF. Archived from the original on 26 April 2012.
- "Ivermectin History". Stanford University. February 24, 1981.
- Onchocerciasis: Africa's victory over river blindness, Africa Recovery, Vol. 17 No. 1 (May 2003), p. 6
- "History". Mectizan. 29 January 2018.
- Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA (February 1989). "Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use". Gastroenterology. 96 (2 Pt 2 Suppl): 647–55. doi:10.1016/S0016-5085(89)80061-7. PMID 2909442.
- "Shocker! Is Vioxx Coming Back... as an Orphan Drug?". www.medpagetoday.com. 2018-05-02.
- Berenson, Alex; Harris, Gardiner; Meier, Barry; Pollack, Andrew (November 14, 2004). "Despite Warnings, Drug Giant Took Long Path to Vioxx Recall". The New York Times. ISSN 0362-4331.
- "The Vioxx Fallout". American Enterprise Institute. September 30, 2005.
- Vaithianathan R, Hockey PM, Moore TJ, Bates DW (2009). "Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey". Drug Saf. 32 (4): 335–43. doi:10.2165/00002018-200932040-00007. PMID 19388724. S2CID 41806262.
- Berenson, Alex (May 30, 2008). "Courts Reject Two Major Vioxx Verdicts". The New York Times.
- "Merck Agrees to Pay $4.85 Billion in Vioxx Claims". The New York Times. November 9, 2007.
- "Description of Settlement Agreement" (PDF). Vioxx MDL Plaintiffs’ Steering Committee Official Vioxx Settlement. November 9, 2007.
- Giles, J. (November 2008). "How Merck Made a Killing". Healthy Scepticism. Archived from the original on October 27, 2008. Alt URL
- Rout, Milanda (April 1, 2009). "Vioxx maker Merck and Co drew up doctor hit list". The Australian.
- Arizona gets $2.3 Million from Vioxx Settlement 92.3 KTAR Retrieved May 19, 2008
- "Merck Agrees to Settlement Over Vioxx Ads". The New York Times. Associated Press. May 20, 2008.
- "Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society". Menopause. 17 (1): 25–54, quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID 20061894. S2CID 7980731.
- Hauk, Lisa (August 2013). "ACOG releases practice bulletin on osteoporosis". American Family Physician. 88 (4): 269–75. PMID 23944732.
- Compston J, Bowring C, Cooper A, et al. (August 2013). "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013". Maturitas. 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID 23810490.
- Eriksen EF, Díez-Pérez A, Boonen S (January 2014). "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review". Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID 24120384.
- Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis". Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID 24063695. S2CID 20163452.
- Gauthier K, Bai A, Perras C, et al. (2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet]". PMID 24278999. Cite journal requires
- "Merck agrees to proposed $27.7 million settlement over Fosamax lawsuits". Reuters. December 9, 2013.
- Johnson, Carrie (February 8, 2008). "Merck to Pay $650 Million In Medicaid Settlement". The Washington Post.
- "Merck to Pay More than $650 Million to Resolve Claims of Fraudulent Price Reporting and Kickbacks" (Press release). United States Department of Justice. February 7, 2008.
- "Merck Resolves Federal and State Investigations Related to Certain Past Pricing And Certain Past Sales and Marketing Activities". FierceBiotech. February 7, 2008.
- Hurdle, Jon (February 7, 2008). "Merck reaches settlement in Medicaid rebate probe". Reuters.
- Connolly, Allison; Kitamura, Makiko (February 10, 2014). "A Tale of Two Mercks as Protesters Take On Wrong Company". Bloomberg News.
- "Merck KGaA, Darmstadt, Germany Announces Favorable UK Court Ruling on Name Use". FiercePharma. January 15, 2016.
- "Judgment 4A_335/2019 of 29 April 2020". Federal Supreme Court of Switzerland. April 29, 2020.
- "Merck & Co., Inc. Settlement". United States Environmental Protection Agency. 9 May 2013.
|Wikimedia Commons has media related to Merck & Co., Inc..|
- Official website
- Business data for Merck & Co.: